Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

MEN-ENDO: Menstrual Stem Cells in Endometriosis

5 mei 2026 bijgewerkt door: Francisco Algaba Chueca

Study of the Role of Menstrual Blood-derived Stem Cells and the Immune Environment in Endometriosis

Endometriosis is a chronic inflammatory condition characterized by the presence of endometrium-like tissue outside the uterine cavity. It is estimated to affect approximately 10% of women of reproductive age and it is associated with chronic pelvic pain and infertility, among other symptoms.

Endometriosis involves complex changes in the body's cells and immune response. For this reason, the goal of this observational study is to characterize the functional, molecular, and immunological alterations in menstrual blood-derived stem cells (MenSCs) and differentiated decidual stromal cells in women with endometriosis; to validate these findings in endometrial tissue and endometriomas; and to establish their correlation with clinical parameters, with the aim of identifying key pathogenic mechanisms and potential therapeutic targets.

The main questions it aims to answer are:

  • Are there functional and molecular changes in MenSCs from patients with endometriosis compared to healthy volunteers?
  • Are there any variations in the immune properties of MenSCs throughout the menstrual bleeding period in patients with endometriosis compared to healthy volunteers?
  • Are these changes also present in endometrial tissue and endometrioma samples?
  • Can these changes be correlated with clinical parameters in patients with endometriosis?
  • Can MenSCs serve as a potential therapeutic target for endometriosis?

Some participants will be asked to provide menstrual blood on a single day, while others will provide samples during the first five days of menstruation. Additionally, all participants will answer questionnaires about their diet, physical activity, stress, and pain levels. Therefore, the study does not involve the evaluation of a specific intervention on the participants.

The results will enable the identification of key altered mechanisms and potential therapeutic targets, thereby contributing to the development of more effective strategies for the diagnosis and treatment of the disease.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Studietype

Observationeel

Inschrijving (Geschat)

40

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

  • Spanje
    • Tarragona
      • Reus, Tarragona, Spanje, 43201
        • Actief, niet wervend
        • Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut
      • Tarragona, Tarragona, Spanje, 43005

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen

Accepteert gezonde vrijwilligers

Ja

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Our study population consists of 40 women aged between 18 and 45, 20 of whom have been diagnosed with endometriosis and 20 of whom are healthy volunteers. Participants will be recruited from the Department of Gynecology and Obstetrics at the Hospital Universitari Joan XXIII in Tarragona (Spain) during routine gynecological check-ups. Healthy volunteers will be selected through individual matching with participants in the study group, considering relevant demographic and clinical variables such as age and ethnic group.

In addition, a sub-cohort of 10 women (5 per study group) will be selected from the main cohort to study in greater detail the intra-menstrual variations in the immunomodulatory properties of MenSCs. This sub-cohort will include participants who agree to provide menstrual blood samples from days 1 to 5 (both inclusive) to analyze dynamic changes in the cells obtained, while maintaining the same general inclusion and exclusion criteria as in the main study.

Beschrijving

Inclusion Criteria:

  • 18-45 years.
  • Endometriosis group: Women with clinical and/or ecographical diagnostic of endometriosis.
  • Control group: Women with the endometriosis diagnosis.

Exclusion Criteria:

  • <18 years or >45 years.
  • Pregnancy or lactation.
  • Diagnosis of prior chronic pelvic inflammatory or autoimmune disease.
  • History of active gynecological cancer.
  • Positive for human immunodeficiency virus (HIV) or human papillomavirus (HPV).
  • Hormonal therapy use in the previous 3 months.
  • Use of immunosuppressants or corticosteroids in the previous 3 months.
  • Systemic antibiotics use in the previous 3 months.
  • Insufficient menstrual flow to allow the MenSCs isolation.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Endometriosis
Ander: Menstrual blood-derived stem cells collection and in vitro characterization
Menstrual-blood derived stem cells will be isolated from the menstrual blood of patients with endometriosis and healthy volunteers to be characterized in vitro.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
MenSCs proliferation rate
Tijdsspanne: Through study completion (average of 3 years)
Evaluation of the expansion capacity of MenSCs from endometriosis patients vs. healthy controls using the MTT assay.
Through study completion (average of 3 years)
Phenotypic characterization of MenSCs
Tijdsspanne: Through study completion (average of 3 years).
Evaluation of surface marker expression using flow cytometry to determine the phenotype of MenSCs from endometriosis patients and healthy controls.
Through study completion (average of 3 years).
MenSC chemotaxis
Tijdsspanne: Through study completion (average of 3 years)
Assessment of the number of T-lymphocytes and monocytes capable of migrating through a transwell membrane under the stimuli of conditioned media from MenSCs obtained from endometriosis patients and healthy controls.
Through study completion (average of 3 years)
MenSC invasion capacity
Tijdsspanne: Through study completion (average of 3 years)
Assessment of the number of MenSCs from endometriosis patients vs. healthy controls capable of degrading a Matrigel on a transwell membrane and migrating toward a chemoattractant.
Through study completion (average of 3 years)
Multilineage capacity of MenSCs
Tijdsspanne: Through study completion (average of 3 years)
The differentiation potential of MenSCs from endometriosis patients vs. healthy controls towards osteocytes, chondrocytes and adipocytes will be assessed by using specific media.
Through study completion (average of 3 years)
Decidualitzation response to progesterone of the decidual cells differentiated from MenSCs from endometriosis patients and healthy volunteers
Tijdsspanne: Through study completion (average of 3 years).
MenSCs will be cultured in presence of 8-Br-cAMP during 14 days, and the assessment of morphology and expression of decidual markers will be performed by RT-qPCR and ELISA assay.
Through study completion (average of 3 years).
Apoptosis resistance assessment of the decidual cells differentiated from MenSCs from endometriosis patients and healthy volunteers
Tijdsspanne: Through study completion (average of 3 years).
Apoptosis resistance will be evaluated by Annexin V/PI flow cytometry following induction by TNFα. Additionally, the expression of key apoptotic mediators will be quantified using RT-qPCR and Western blot.
Through study completion (average of 3 years).
Cytokine profile of the secretome of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells.
Tijdsspanne: Through study completion (average of 3 years).
The conditioned media will be assessed to determine the cytokines secreted using an ELISA assay.
Through study completion (average of 3 years).
Cytokine profile of the endometrial and endometrioma tissues
Tijdsspanne: Through study completion (average of 3 years).
The levels of cytokines in the conditioned media from cultured explants will be assessed by ELISA assay.
Through study completion (average of 3 years).
Cytokine profile of the secretome of immune cells populations
Tijdsspanne: Through study completion (average of 3 years)
The levels of cytokines in the conditioned media from lymphocytes and macrophages will be assessed by ELISA assay.
Through study completion (average of 3 years)
Cytokine profile of the peripheral blood plasma
Tijdsspanne: Through study completion (average of 3 years)
The levels of cytokines in peripheral blood plasma from endometriosis patients and healthy volunteers will be determined by ELISA assay.
Through study completion (average of 3 years)
Gene expression profile of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells
Tijdsspanne: Through study completion (average of 3 years)
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
Through study completion (average of 3 years)
Gene expression profile of the endometrial and endometrioma tissues
Tijdsspanne: Through study completion (average of 3 years).
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
Through study completion (average of 3 years).
Gene expression profile of the immune cells populations
Tijdsspanne: Through study completion (average of 3 years)
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
Through study completion (average of 3 years)
Protein expression of MenSCs from endometriosis patients and healthy volunteers and their differentiated decidual cells
Tijdsspanne: Through study completion (average of 3 years)
Analysis of the protein expression profile via Western Blot.
Through study completion (average of 3 years)
Protein expression in endometrial and endometrioma tissues
Tijdsspanne: Through study completion (average of 3 years)
Analysis of the protein expression profile via Western Blot.
Through study completion (average of 3 years)
Protein expression in immune cells populations
Tijdsspanne: Through study completion (average of 3 years)
Analysis of the protein expression profile via Western Blot.
Through study completion (average of 3 years)
T cells activation
Tijdsspanne: Through study completion (average of 3 years)
T cells will be exposed to conditioned media from MenSCs from healthy volunteers and endometriosis patients. Afterwards, the levels of IL-10 and IFNy will be determined by ELISA assay.
Through study completion (average of 3 years)
T cells proliferation rate
Tijdsspanne: Through study completion (average of 3 years)
T cells will be exposed to conditioned media from MenSCs from healthy volunteers and endometriosis patients. Afterwards, their proliferative capacity will be assessed by MTT assay.
Through study completion (average of 3 years)
Cytokine secretion profile of macrophages
Tijdsspanne: Through study completion (average of 3 years)
The levels of cytokines in the supernatant of polarized macrophages after incubation with MenSC-derived conditioned media from endometriosis patients and healthy volunteers will be determined by ELISA assay.
Through study completion (average of 3 years)
Gene expression profile of macrophages
Tijdsspanne: Through study completion (average of 3 years)
Total RNA expression of targeted genes will be analyzed by RT-qPCR.
Through study completion (average of 3 years)
Protein expression of macrophages
Tijdsspanne: Through study completion (average of 3 years)
Analysis of the protein expression profile via Western Blot.
Through study completion (average of 3 years)
Phagocytic capacity of macrophages
Tijdsspanne: Through study completion (average of 3 years)
Assessment of the macrophages' ability to engulf fluorescently labeled apoptotic bodies from MenSCs via flux cytometry and fluorescence microscopy.
Through study completion (average of 3 years)
Angiogenic potential of macrophages conditioned media
Tijdsspanne: Through study completion (average of 3 years)
Evaluation of the ability of macrophage-derived conditioned media to induce tube formation (Matrigel) in Human Umbilical Vein Endothelial Cells (HUVECs).
Through study completion (average of 3 years)
Exploration of targeted interventions to reverse the pathological phenotype of MenSCs and macrophages derived from menstrual blood.
Tijdsspanne: Through study completion (average of 3 years).
Signaling pathways and genes involved in the altered phenotype will be blocked and silenced, respectively, to evaluate if these actions reverse the cellular response to the levels of the healthy volunteers' cells.
Through study completion (average of 3 years).
Correlation of cellular, tissue and molecular findings with patients' clinical parameters.
Tijdsspanne: Through study completion (average of 3 years).
The associations among the functional and immunological properties of MenSCs and macrophages, clinical parameters and dietary and behavioral habits will be stablished. These clinical parameters include endometriosis stage, pain and fertility status, and the extent and localization of the endometriosis foci.
Through study completion (average of 3 years).

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Francisco Algaba Chueca

Medewerkers

Hospital Universitari Joan XXIII de Tarragona.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 april 2026

Primaire voltooiing (Geschat)

1 oktober 2027

Studie voltooiing (Geschat)

1 april 2028

Studieregistratiedata

Eerst ingediend

13 april 2026

Eerst ingediend dat voldeed aan de QC-criteria

5 mei 2026

Eerst geplaatst (Werkelijk)

11 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

11 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

5 mei 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • MEN-ENDO CEIm 308/2025

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren